(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
02 November 2023 (02.11.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/209568 A1

(51) International Patent Classification:
C07K 16/24 (2006.01) *A61P 37/00* (2006.01)
C07K 16/46 (2006.01) *A61K 39/395* (2006.01)
A61P 17/00 (2006.01) *A61K 39/00* (2006.01)

(21) International Application Number:
PCT/IB2023/054248

(22) International Filing Date:
25 April 2023 (25.04.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/334,964 26 April 2022 (26.04.2022) US

(71) Applicant: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, 4056 Basel (CH).

(72) Inventor; and
(71) Applicant: **ROTH, Lukas** [CH/CH]; NOVARTIS PHARMA AG, Postfach, 4002 Basel (CH).

(72) Inventors: **BARDROFF, Michael Otto**; NOVARTIS PHARMA AG, Postfach, 4002 Basel (CH). **CEBE, Regis**; NOVARTIS PHARMA AG, Postfach, 4002 Basel (CH). **KOVARIK, Jiri**; NOVARTIS PHARMA AG, Postfach, 4002 Basel (CH). **KOLBINGER, Frank**; NOVARTIS PHARMA AG, Postfach, 4002 Basel (CH). **KIFFE, Michael**; NOVARTIS PHARMA AG, Postfach, 4002 Basel (CH). **RITTER, Anett**; NOVARTIS PHARMA AG, Postfach, 4002 Basel (CH).

(74) Common Representative: **NOVARTIS AG**; Lichtstrasse 35, 4056 Basel (CH).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*
— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*

(54) Title: MULTISPECIFIC ANTIBODIES TARGETING IL-13 AND IL-18

(57) Abstract: Described herein are multispecific antibodies targeting IL-13 and IL-18. The multispecific antibodies can be antagonistic and/or therapeutic antibodies targeting IL-13 and IL-18. Also described herein are methods of making said multispecific antibodies, methods of inhibiting IL- 13 and IL-18 simultaneously with said multispecific antibodies, and methods of treating an IL- 13/IL-18 mediated disorder, such as atopic dermatitis, by administering a multispecific antibody described herein.

WO 2023/209568 A1